Background: Limited data are available on the prognostic value of changes in the biological features of residual tumours following neoadjuvant therapies in breast cancer patients.
introduction
Neoadjuvant therapy is useful in order to improve operability and to obtain in vivo information about the sensitivity of tumours to the treatments [1, 2] . The achievement of pathological complete response ( pCR) is a valid surrogate of better survival [3, 4] . However, only a minority of patients achieve a pCR after therapy while the vast majority of patients have residual disease in the breast or axilla at final surgery [5] .
In the metastatic setting, several authors have reported changes in receptor status between primary cancer and metastatic sites [6, 7] .
Limited data are available on the prognostic value of changes in the biological features of residual tumours following neoadjuvant therapies. Previous authors have reported that the change is remarkable for hormonal receptors-positive tumours [8] . Mittendorf et al. reported that one-third of patients with significant residual disease loses HER2 amplification, and this change is associated with poor outcome [9] .
The post-chemotherapy Ki-67 is a strong predictor of outcome for patients not achieving a pCR. [10] [11] [12] [13] . Moreover, the value of Ki-67 after short-term presurgical endocrine therapy may have a prognostic role [14] . The post endocrine neoadjuvant treatment value of Ki-67 was also integrated in a model for outcome prediction [15] .
The objective of our study is to assess the frequency of the change in biological features between the diagnostic core biopsy and final surgery in patients with residual disease after neoadjuvant chemotherapy. We also assess the impact of biological feature changes on long-term outcome.
patients and methods patients and treatments
We extracted information from the institutional clinical database on all consecutive breast cancer patients treated at the European Institute of Oncology (EIO), Milan, Italy, between 1999 and 2011. Data on the patient's medical history, concurrent diseases, type of surgery, histo-pathological features and results of staging procedures were reviewed. We selected patients who did not achieve pCR at final surgery after neoadjuvant chemotherapy.
Following final surgery, all cases were discussed during the weekly multidisciplinary meeting. Women were usually followed up by physical examination every 6 months and annual mammography, with or without breast ultrasound (US). In symptomatic cases or when clinically indicated, a bone scan, chest X-ray, liver US or computed tomography scan were carried out.
The selection of a neoadjuvant treatment was individually based on indicators of responsiveness to treatment, comorbidity and clinical stage.
In the case of luminal B disease, patients were treated with preoperative chemotherapy administered in 3-week courses. Patients achieving partial remission or complete remission were candidates to receive a maximum of eight courses. The regimens used during the study included anthracyclinecontaining, taxane-containing and navelbine-containing regimens and others as previously reported [16] . Patients with triple-negative breast cancer were candidates for cisplatin-containing chemotherapy or alkylating-containing chemotherapy for 6 months.
In cases of HER2 overexpression and/or amplification, trastuzumab was added to neoadjuvant therapy not including anthracycline, and was prescribed starting from 2004.
Postoperative local-regional irradiation (RT) was proposed to all patients who underwent breast-conserving surgery, to patients with cT4 disease and whenever indicated.
The selection of adjuvant systemic treatment was based on indicators of responsiveness to treatment and evaluation of risk. For patients with endocrine-responsive disease, adjuvant endocrine therapy alone according to menopausal status was prescribed (tamoxifen or aromatase inhibitor) for a duration of 5 years in postmenopausal patients while, for premenopausal patients, a combination of tamoxifen for 5 years plus gonadotropin-releasing hormone analogues for at least 2 years was prescribed [17] .
pathology and immunohistochemistry
This is a single-institution study. All patients had a pathological evaluation carried out on the diagnostic core biopsy and on the residual tumour at final surgery at the EIO.
Surgical specimens were extensively sampled for the evaluation of residual tumour after primary therapy. In cases of lack of gross evidence of tumour, the breast-conserving surgery specimens were entirely blocked in paraffin and examined histologically, as were the tumour-bearing quadrants of the mastectomies. In the latter case, the other quadrants were also thoroughly evaluated by examining at least three tissue blocks.
Patients who achieved pCR were excluded from the present analyses. The pCRs were evaluated according to the criteria of Kuerer et al. [4] . In particular, the absence of invasive cancer on both the primary breast tumour and axillary lymph nodes qualified for pCR.
Immunostaining experiments for the localization of ER and PgR, HER2 protein and Ki-67 antigen were carried out on consecutive tissue sections from the tumour-containing blocks, as previously reported [16] . The following primary antibodies were used: the 1D5 monoclonal antibody (mAb) to ER (Dako, Glostrup, Denmark at 1/100 dilution), the mAb to PgR (Dako, 1/800), the MIB-1 mAb to the Ki-67 antigen (Dako, 1 : 100), and the polyclonal antiserum (Dako, 1/800) to the HER2 protein.
Only nuclear reactivity was taken into account for ER, PgR, and Ki-67 antigen, whereas only an intense and complete membrane staining in >10% of the tumour cells qualified for HER2 overexpression (3+). The results for ER, PgR and Ki-67 were recorded as the percentage of immunoreactive cells over at least 2000 neoplastic cells. The value of 20% for Ki-67 labelling index (LI) was used as a cut-off in distinguishing tumours with low (<20%) and high (>20%) proliferative fraction [16] . Steroid hormone receptor status was classified as negative in case of lack of any ER and PgR immunoreactivity, o < 1% immunoreactive tumour cells. In accordance with the results by Prat et al. for PgR expression, we divided the tumours into luminal B-like (incompletely endocrine responsive) (PgR <20%of the cells) or luminal A-like (highly endocrine responsive) (PgR 20% of the cells) [18] .
statistical analysis
The paired t-test was used to test the hypothesis of a null change from biopsy to surgery in ER, PgR and Ki-67 expression. The mean absolute changes, along with the 95% confidence intervals (CIs) were reported.
Disease-free survival (DFS) was defined as the length of time from the date of surgery to any relapse (including ipsilateral breast recurrence), the appearance of a second primary cancer (including contralateral breast cancer) or death, whichever occurred first.
Overall survival (OS) was determined as the time from the date of surgery until the date of death (from any cause).
Plots of the survival curves were drawn using the Kaplan-Meier method. The log-rank test was used to assess survival differences between groups identified by ER, PgR and Ki-67 patterns of changes from biopsy to surgery. We considered four different patterns of changes for ER (i.e. from negative to negative, from negative to positive, from positive to negative and from positive to positive), PgR and Ki-67 (i.e. from <20% to <20%, from <20% to 20%, from 20% to <20% and from 20% to 20%).
Multivariable Cox proportional hazard regression models were used to assess the effect of pattern of changes of biological variables adjusted for other prognostic factors, including menopausal status, grade, pT, pN, HER2 status and peri-tumoral vascular invasion. Results from Cox models were expressed as hazard ratios (HRs) with 95% CIs.
All analyses were carried out with the SAS software version 9.1 (Cary, NC). All P values were two sided.
Moreover, to investigate the potential modifying effect of concomitant endocrine treatment (No versus Yes) and molecular subtype on the effects of PgR and Ki-67 down-regulation, we fitted multivariable Cox models considering pattern of change, type of neoadjuvant treatment or molecular subtype and their interaction terms. Wald test was used to evaluate the hypothesis of homogeneity of the effect of biological changes in the different subgroups of patients (e.g. CT only versus CT/HT).
results
We identified a total of 2282 patients who received neoadjuvant chemotherapy at the EIO, Milan, Italy, between 1999 and 2011. We excluded patients who achieved pCR and patients whose breast cancers had incomplete biological assessments at diagnostic core biopsy and/or final surgery. Finally, we selected a total of 904 patients for the present analyses (supplementary Figure S1 , available at Annals of Oncology online)
The median follow-up was 7.2 years (range 4 months-14.5 years). Table 1 shows the clinical-pathological features of the patients at the time of diagnostic core biopsy: 62% of the patients were premenopausal; the majority presented hormonal receptor-positive disease, and clinical T4 in 30% of cases. The Ki-67 LI was high (>20% of the cells) in 79% of patients.
Supplementary Figure S2 , available at Annals of Oncology online, shows the quantitative changes in biological features between diagnostic core biopsy and surgery in all patients. The mean decrease was 1.3 and 14.1 points for ER and PgR expression, respectively. Ki-67 LI expression decreased at final surgery with a medium value of 9.7 points. Supplementary Figure S3 , available at Annals of Oncology online, reports the qualitative changes, in biological features including HER2 status, between diagnostic core biopsy and surgery. A total of 5% of patients with ER-positive tumour at diagnostic biopsy had ER-negative residual disease. For PgR status, 67% of patients, whose tumours had a PgR 20% at diagnostic biopsy had a PgR <20% at final surgery.
The Ki-67 LI changed from 20% to <20% in 40% of patients.
Fourteen percent of patients with HER2-positive tumour at biopsy had HER2-negative residual at surgery. Conversely, 4% initially HER2-negative patients became HER2 positive at surgery. Figure 1 reports the outcome according to type of qualitative ER and PgR changes. No difference in terms of DFS and OS were reported in patients treated with hormonal adjuvant therapy according to type of qualitative ER change. Conversely, the change of PgR had a prognostic impact.
Patients who presented a decrease of PgR at final surgery (>20% to <20%) had a better outcome in terms of DFS and OS ( Figure 1B) .
Worse outcome was reported for patients whose tumours at final surgery presented an increase of Ki-67 (<20%->20%) as reported in Figure 1 (C) .
multivariate analysis
We confirmed the prognostic role of classical clinical biological features correlated with higher risk of worse outcome, such as larger tumour size, positive nodal involvement and ER negativity, at multivariate analysis (Table 2) .
Moreover, the decrease of PgR at final surgery (from 20% at biopsy) was correlated with better outcome in terms of DFS (HR 0.73, 95% CI 0.54-1.00, P 0.046), when compared with patients with PgR <20% both at biopsy and at surgery.
The positive effect of reduction of PgR at surgery was confirmed in both groups, when we analysed the effect separately in patients treated with chemotherapy alone or chemoendocrine treatment in terms of DFS (HR = 0.51 in No endocrine treatment (ET) versus HR = 0.71 in Yes ET, P = 0.256). In term of OS, the protective effect was more relevant for the patients treated with chemotherapy alone compared with the concomitant treatment (Table 3 ).
In addition, the change of Ki-67 expression from 20% at diagnostic core biopsy to <20% at final surgery was found to be associated with better outcome in terms of DFS (HR 0.52; 95% CI 0.40-0.68, P < 0.0001) and OS (HR 0.45; 95% CI 0.32-0.64, P < 0.0001), when compared with patients with Ki-67 20% at surgery. This result was confirmed in patients treated with chemotherapy alone or chemo-endocrine treatment (Table 3) . No substantial differences were reported on DFS and OS when we analysed the effect of PgR and Ki-67 changes, stratified by molecular subtypes (Table 4) .
discussion
The response to neoadjuvant treatment may be utilized as a prognostic marker and the achievement of pCR has been adopted as the primary end point for neoadjuvant trials [1] [2] [3] [4] . Recently, Cortazar et al. in a pooled analyses confirmed the prognostic value of pCR but challenge the validity of pCR as surrogate marker of treatment benefit [19] On the other hand, the pCR can only be achieved in 20%-40% cases and it is crucial to identify the clinical-pathological features at final surgery that might play a prognostic role in patients with residual disease At univariate analysis in the subgroup of patients with low level of 
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Chen et al. reported that a negative switch in hormonal receptor status leads to a poor outcome regardless of adjuvant endocrine therapy [8] . Unlike the present study, however, ER and PgR were not evaluated separately.
ER-positive/PgR-negative tumours represent a distinct subset of breast cancer with aggressive features and poor outcome despite being clinically endocrine responsive [20] . The prognostic and predictive value of PgR has long been ascribed to the dependence of PgR expression on ER activity, with the absence of the PgR reflecting a non-activated or non-functional ER, with a consequent resistance to hormonal therapy. Moreover, the absence of PgR may reflect hyperactive cross-talk between ER and growth factor signalling pathways that reduce PgR even as they activate other ER functions [21] . Prat et al. reported that semi-quantitative IHC expression of PgR improves the identification of good outcome breast cancers of luminal disease [18] . Following the same approach, Cancello et al. reported that PgR loss identifies luminal B breast cancer subgroups at higher risk of relapse [22] .
Our results indicate that the reduction or loss of PgR expression after preoperative chemotherapy has a positive impact on outcome for breast cancer patients. In this setting, low expression of PgR does not have the same prognostic implications as it does in other settings.
The modification of PgR expression may in fact be correlated to the endocrine effect of chemotherapy.
This effect might be particularly relevant in our study where 60% of the patients were premenopausal with more than half of them presenting an endocrine-responsive disease. Previous studies have reported that the premenopausal patients with ERpositive tumours who achieved chemotherapy-induced amenorrhoea had a significantly improved outcome [23, 24] .
Also women of postmenopausal age may obtain some additional endocrine effect from suppression of the adrenals due to cytotoxics and steroids [25] .
We also reported that, at univariate analysis, patients having a decrease of Ki-67 from biopsy to surgery had a better prognosis than patients with a high level of Ki-67 expression at surgery, both in terms of DFS and OS. The protective effect of Ki-67 decrease was confirmed in the multivariate analysis. The prognostic role of final value of Ki-67 LI after preoperative chemotherapy was also reported in some previous studies [10] [11] [12] [13] .
In conclusion, we have identified a prognostic role for a decreased expression of PgR and Ki-67 LI after preoperative chemotherapy in breast cancer patients. Assessment of these changes may be useful to identify subsets of patients with better outcome after neoadjuvant chemotherapy even if pCR is not achieved.
